S&P TSX Capped Composite...

US Dollar vs CAD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

Home
Investing
Stocks
UK
LSE
Selvita Sa (0RKT)
Selvita Sa (0RKT) News

0RKT

Selvita (0RKT)

Selvita Sa

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:LSE:0RKT

Date	Time	Source	Headline	Symbol	Company
10/23/2024	7:26AM	PR Newswire (US)	Ryvu Therapeutics presents clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium	LSE:0RKT	Selvita Sa
10/09/2024	5:53AM	PR Newswire (US)	Ryvu Therapeutics to present clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium	LSE:0RKT	Selvita Sa
09/23/2024	9:31AM	PR Newswire (US)	Ryvu Therapeutics to present ONCO Prime platform at the 6th Annual RAS-Targeted Drug Development Summit	LSE:0RKT	Selvita Sa
06/14/2024	10:40AM	PR Newswire (US)	Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress	LSE:0RKT	Selvita Sa
03/06/2024	3:40AM	UK Regulatory	Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting	LSE:0RKT	Selvita Sa
02/14/2024	12:12PM	UK Regulatory	Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS	LSE:0RKT	Selvita Sa
11/02/2023	10:02AM	PR Newswire (US)	Ryvu Therapeutics to Present Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting	LSE:0RKT	Selvita Sa
09/28/2022	12:17PM	PR Newswire (US)	Ryvu Therapeutics Reports 2022 Half-Year Financial Results and Provides Corporate Update	LSE:0RKT	Selvita Sa
06/10/2022	4:54AM	PR Newswire (US)	Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress	LSE:0RKT	Selvita Sa
03/08/2022	3:50PM	PR Newswire (US)	Ryvu Therapeutics to Present Data from its Oncology Programs at AACR 2022 Annual Meeting	LSE:0RKT	Selvita Sa
06/11/2021	3:30AM	PR Newswire (US)	Ryvu Therapeutics Presents Positive Phase I Data for RVU120 at the Virtual 26th Annual Congress of the European Hematology As...	LSE:0RKT	Selvita Sa
05/28/2021	7:08AM	PR Newswire (US)	Ryvu Therapeutics got full approval to conduct Phase I/II study of RVU120 (SEL120) in patients with relapsed/refractory metas...	LSE:0RKT	Selvita Sa
01/04/2021	3:05PM	PR Newswire (US)	Selvita completes acquisition of Fidelta from Galapagos	LSE:0RKT	Selvita Sa
12/01/2020	6:10AM	PR Newswire (US)	Three Posters on SEL24/MEN1703 including Pharmacodynamic Data from the Dose Escalation Part of DIAMOND-01 Trial to be publish...	LSE:0RKT	Selvita Sa
09/10/2020	5:51AM	PR Newswire (US)	Selvita reports strong financial results for H1 2020 and a record backlog	LSE:0RKT	Selvita Sa
06/10/2020	11:58AM	PR Newswire (US)	Ryvu Therapeutics Reports First Quarter 2020 Financial Results	LSE:0RKT	Selvita Sa
06/02/2020	9:20AM	PR Newswire (US)	Ryvu Therapeutics Has Completed the Construction of the R&D Center for Innovative Drugs	LSE:0RKT	Selvita Sa
05/26/2020	1:24AM	PR Newswire (US)	Selvita Reports Financial Results for Q1 2020: Dynamic Increase in Backlog for 2020 and Strong Position on the Market	LSE:0RKT	Selvita Sa
05/14/2020	8:30AM	PR Newswire (US)	Ryvu Therapeutics Announces Availability of Abstracts Regarding Phase 1/2 Study of SEL120 and SEL24/MEN1703 Accepted for Pres...	LSE:0RKT	Selvita Sa
04/27/2020	2:33AM	PR Newswire (US)	Selvita and Ardigen Will Receive Funding for the Development of an AI-based High-content Screening Platform	LSE:0RKT	Selvita Sa
04/16/2020	1:12AM	PR Newswire (US)	Galapagos and Ryvu Announce Research Collaboration	LSE:0RKT	Selvita Sa
02/27/2020	5:00AM	PR Newswire (US)	Ryvu Therapeutics to Present Recent Data From Multiple Oncology Programs at AACR 2020 Annual Meeting	LSE:0RKT	Selvita Sa
11/07/2019	5:30AM	PR Newswire (US)	Selvita Q3 2019 Results: Accelerated Growth, 45 Percent Increase in Commercial Revenues and Strong Long-term Outlook	LSE:0RKT	Selvita Sa
11/06/2019	10:39AM	PR Newswire (US)	Ryvu Therapeutics Announces Presentations on CDK8 Inhibitor SEL120 at the 61st ASH Annual Meeting	LSE:0RKT	Selvita Sa
11/06/2019	7:00AM	PR Newswire (US)	Ryvu Therapeutics Reports Third Quarter 2019 Financial Results	LSE:0RKT	Selvita Sa
10/01/2019	9:00AM	PR Newswire (US)	Ryvu Therapeutics and Selvita Announce Registration of Corporate Split by the National Court Register of Poland	LSE:0RKT	Selvita Sa
09/06/2019	1:00AM	PR Newswire (US)	Selvita Announces First Patient Dosed in Phase 1b Study of CDK8 Inhibitor SEL120 in the Treatment of Acute Myeloid Leukemia o...	LSE:0RKT	Selvita Sa
09/05/2019	1:00AM	PR Newswire (US)	Selvita Reports Second Quarter and Half-year 2019 Financial Results	LSE:0RKT	Selvita Sa
09/03/2019	12:00PM	PR Newswire (US)	Polish Financial Supervision Authority Approves Selvita CRO Prospectus, Allowing Corporate Split Into Two Separately Listed C...	LSE:0RKT	Selvita Sa
09/03/2019	4:00AM	PR Newswire (US)	Selvita to Present at Upcoming Conferences in September	LSE:0RKT	Selvita Sa

Showing the most relevant articles for your search:LSE:0RKT

Vogiatzoglou Systems

Invesco QQQ Trust Series 1

Vanguard FTSE Dev All Ca...

Seamless Distribution Ab

Bos(shd)n1.m-bk

Atlantic Coastal Acquisi...

MEDIROM Healthcare Techn...

S&P ASX 200 A REIT OPIC

Aclaris Therapeutics

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions